Co-Vaccination of PCV2 and Lawsonia Intracellularis Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccination strategies for swine herds face challenges in effectively distinguishing between Porcine Circovirus Associated Diseases (PCVAD) caused by PCV2 and ileitis caused by Lawsonia intracellularis, leading to confusion and potential mismanagement, with no co-vaccination strategy available for simultaneous prevention or treatment.
Innovation Solution
Administering a combination of PCV2 antigen and L. intracellularis antigen to swine to enhance immunogenic potential and reduce clinical symptoms associated with both infections, using specific antigens like Ingelvac® CircoFLEX™ for PCV2 and Enterisol® Ileitis or Enterisol® Ileitis B3903 for L. intracellularis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate vaccination strategies are used for PCV2 and L. intracellularis, then individual disease protection is achieved, but diagnostic confusion and management complexity increase due to similar clinical symptoms
Solution Approach 1:
The patent combines separate vaccination strategies into a unified co-vaccination approach by administering both PCV2 antigen and L. intracellularis antigen together. This merging resolves the contradiction by maintaining individual disease protection while simplifying management through a single integrated vaccination protocol that addresses both pathogens simultaneously.
Solution Approach 2:
The co-vaccination strategy serves multiple functions: it protects against both PCV2 and L. intracellularis infections, reduces diagnostic confusion from overlapping symptoms, and provides comprehensive protection in a single intervention. This multi-functionality resolves the contradiction by achieving reliable protection without increasing strategy complexity.
2Reliability
If co-vaccination with PCV2 and L. intracellularis antigens is administered, then synergistic immune response and reduced clinical symptoms are achieved, but vaccination protocol complexity increases
Solution Approach 1:
The patent merges PCV2 vaccination and L. intracellularis vaccination into a single co-vaccination protocol administered simultaneously or in close sequence. This combining approach achieves synergistic immune responses while managing protocol complexity through integrated administration guidelines and standardized dosing schedules.
3Measurement precision
If accurate diagnosis is implemented to distinguish PCVAD from ileitis, then appropriate treatment is achieved, but diagnostic time and resource requirements increase
Solution Approach 1:
The patent applies preliminary action by implementing co-vaccination before disease symptoms fully develop or before diagnostic confusion arises. By preemptively protecting against both PCV2 and L. intracellularis simultaneously, the need for complex differential diagnosis is reduced, thereby maintaining diagnostic accuracy while minimizing diagnostic time and resource requirements.
Data Source
AI summary
The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.